Fipamezole
Given that we were just discussing the need for research to develop noradrenergic drug therapies that work on the noradrenaline receptors...I am happy to share the news that Santhera in Europe has entered into agreement with Biovail to exclusively produce and market Fipamezole (JP-1730) as treatment for PD - it is in clinical trial and targets controlling dyskinesia and prolongs benefit of levodopa. We need this!!! Stay tuned....Phase III trials in US slated for 2011.
http://www.medicalnewstoday.com/articles/161643.php |
All times are GMT -5. The time now is 05:50 AM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.